A snip from the FR"Bank of America Merril Lynch analyst Matt...

A snip from the FR

"Bank of America Merril Lynch analyst Matt Prior questioned the company on its plans in case it received a knock back, as it did in Europe in 2011. Mr Prior has a ‘buy’ on the stock and $2.41 price target and remained positive on the outlook.

“There is optionality for after the advisory committee meeting for Pharmaxis to modify their label in discussions with the FDA,” he said."



http://www.afr.com/p/business/companies/pharmaxis_braces_for_us_review_of_0VIy5wBn2wXpFe9tvQgMbJ


You can sign up for free to see this full article as I did.